encorafenib
Foundation Medicine, Pierre Fabre Laboratories to Collaborate on CDx for Lung Cancer
The companies will seek approval for Foundation Medicine's assays identifying patients for treatment with Pierre Fabre's BRAF/MEK inhibitor combination regimen.
FDA Approves Foundation Medicine CDx Tests for Pfizer's Braftovi-Mektovi Combo in Lung Cancer
The FoundationOne CDx and FoundationOne Liquid CDx tests were approved to determine whether patients with metastatic non-small cell lung cancer may be eligible for treatment.
Amoy Diagnostics, Pierre Fabre Collaborate to Develop CDx in China
The companion diagnostic kits will support marketing authorization applications for Pfizer's Braftovi and Mektovi.
Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.